长春海悦药业

Haiyue Pharmaceutical is a prominent Chinese pharmaceutical enterprise focused on the research, development, and commercialization of high-end generic and innovative small molecule drugs. Headquartered in Changchun, the company has built a comprehensive portfolio targeting cardiovascular diseases, oncology, diabetes, and infectious diseases. Haiyue gained significant industry recognition as the first company to receive approval for a generic version of the anticoagulant Rivaroxaban in China. The company maintains advanced GMP-certified manufacturing facilities and a dedicated R&D center to support its pipeline of complex formulations. With a strong emphasis on quality and innovation, Haiyue Pharmaceutical continues to expand its market share in both domestic and international healthcare sectors.